Skip to main content
. Author manuscript; available in PMC: 2013 Apr 1.
Published in final edited form as: Hepatology. 2012 Feb 15;55(4):1030–1037. doi: 10.1002/hep.24788

Figure 2.

Figure 2

Figure 2

Figure 2

Comparison of measured HCV RNA (circle) and best-fit prediction by the viral kinetic model during the 14-days of treatment with mericitabine monotherapy followed by 14 days of follow-up in three patients treated with 1500 mg BID. The number in each figure indicates the subject number, and the dotted red line the treatment effectiveness. The vertical line indicates the time of treatment cessation. These patients are displayed because they exhibit a monophasic decline (#92407), a biphasic type of decline with a significant increase in antiviral effectiveness in the first week of treatment (#92409), and a flat second phase of viral decline (#92410), where the increase in antiviral effectiveness is rapid, but flattens out and remains stable during the second phase of antiviral decline. Parameters used are given in Table S1.